A new innovative 3D-bioprinted model approach for cancer will enable the development of new drugs, discovery of new drug targets at a much faster rate and facilitates personalized medicine.

‘New 3D- bioprinted cancer model gives access to clinical scenarios with no time limits, enabling optimal investigation.’

Glioblastoma is the most lethal cancer of the central nervous system, accounting for most brain malignancies. In a previous study, researchers identified a protein called P-Selectin, produced when glioblastoma cancer cells encounter microglia – cells of the brain's immune system.




This protein is responsible for a failure in the microglia, causing them to support rather than attack the deadly cancer cells, helping the cancer spread.
As cancer cells behave very differently on a plastic surface than it does in the human body, 90% of all experimental drugs fail at the clinical stage because the success achieved in the lab is not reproduced in patients.
To address this problem, researchers created the first 3D-bioprinted model of a glioblastoma tumor, in which 3D cancer tissue surrounded by extracellular matrix communicates with its microenvironment via functional blood vessels.
"It's not only the cancer cells, It is also the cells of the microenvironment in the brain; the astrocytes, microglia and blood vessels connected to a microfluidic system – namely a system enabling us to deliver substances like blood cells and drugs to the tumor replica”, explains Prof. Satchi-Fainaro.
Advertisement
After successfully printing the 3D tumor, researchers demonstrated that unlike cancer cells growing on petri dishes, the 3D-bioprinted model has the potential to be effective for rapid, robust, and reproducible prediction of the most suitable treatment for a specific patient.
Advertisement
Source-Medindia